International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203

De Novo Drug Design: Emerging Artificial Intelligence-Driven Strategies in Modern Drug Discovery

Rutuja Rajendra Gaikwad[1], Jagruti Jayawant Jagatap[2], Pooja Hanmant Kabade[2], Priya Samadhan Dhane[2], Sanjana Sachin Udugade[2]

1. Assistant Professor Dr. Ashok Gujar Institute of Pharmacy Karad, India.
2. Student Of Ashok Gujar Institute of Pharmacy Karad, India.

Received: 30 March 2026 Revised: 25 April 2026 Accepted: 30 April 2026

ABSTRACT

De novo drug design has emerged as a transformative strategy in pharmaceutical research by enabling the rational generation of novel molecular entities with improved pharmacological properties. Traditional drug discovery approaches are often associated with high costs, long development timelines, and limited success rates. The integration of computational methods, machine learning, and artificial intelligence has significantly improved the efficiency of de novo drug design. This review discusses the principles, methodologies, applications, and recent advancements in de novo drug design with emphasis on AI-driven molecular generation, structure-based drug design, ligand-based methods, and optimization strategies. The article also highlights the role of molecular docking, quantitative structure–activity relationship analysis, virtual screening, and deep learning algorithms in accelerating lead discovery. Furthermore, challenges related to synthetic accessibility, toxicity prediction, and regulatory considerations are critically discussed. The review concludes with future perspectives regarding personalized medicine and autonomous drug discovery platforms.

Keywords ; De novo drug design, Artificial intelligence, Drug discovery, Molecular docking, Machine learning, Virtual screening, QSAR, Computational chemistry

1. INTRODUCTION

Drug discovery is a complex and resource-intensive process that involves the identification, optimization, and validation of bioactive compounds. Conventional drug discovery approaches rely heavily on high-throughput screening and empirical experimentation, which often require extensive financial investment and long development periods. De novo drug design represents an advanced computational approach aimed at designing entirely new molecular structures with desired biological activity.

The concept of de novo drug design is based on constructing novel compounds from molecular fragments or atoms while considering physicochemical properties, biological targets, and pharmacokinetic parameters. Recent developments in computational biology, cheminformatics, and artificial intelligence have accelerated the evolution of this field. The use of machine learning algorithms and neural networks has enabled researchers to generate optimized compounds with enhanced selectivity and reduced toxicity.

The pharmaceutical industry has increasingly adopted de novo drug design methodologies to identify innovative lead compounds against cancer, infectious diseases, neurological disorders, and metabolic syndromes. Modern computational tools have facilitated rapid molecular modeling, prediction of ligand–receptor interactions, and virtual screening of millions of compounds.

2. Principles of De Novo Drug Design

De novo drug design involves the rational generation of molecular structures that can interact effectively with a biological target. The process generally begins with target identification followed by structural characterization of the target protein. Molecular fragments are assembled computationally to create novel chemical entities capable of binding to active sites with high affinity.

The major principles include:

• Optimization of molecular interactions

• Maintenance of pharmacophoric features

• Improvement of physicochemical properties

• Enhancement of pharmacokinetic behavior

• Reduction of toxicity and off-target effects

The process may employ fragment-based assembly, evolutionary algorithms, stochastic searches, and reinforcement learning methods for molecular optimization.

3. Types of De Novo Drug Design

De novo drug design can be broadly classified into structure-based and ligand-based approaches**.**

3.1 Structure-Based Drug Design (SBDD)







International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203

Structure-Based Drug Design (SBDD) –

It is a computational approach used in modern drug discovery where the three-dimensional structure of a biological target, usually a protein, is utilized to design and optimize drug molecules. The target structure is commonly obtained using techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy.

The primary objective of SBDD is to identify compounds that can bind specifically and strongly to the active site of a target protein, thereby producing a desired therapeutic effect.

Principle of SBDD- The principle of structure-based drug design is based on the interaction between a ligand (drug molecule) and the biological target. By understanding the molecular architecture of the target protein, researchers can design molecules that fit precisely into the binding site and form stable interactions such as:

- Hydrogen bonding
- Hydrophobic interactions
- Electrostatic interactions
- Van der Waals forces

This approach helps in improving drug potency, selectivity, and safety.

Steps Involved in SBDD

1. Target Identification and Validation-A disease-related biological target such as an enzyme or receptor is selected and validated.

2. Determination of Protein Structure-The three-dimensional structure of the target protein is determined using:

- X-ray crystallography
- NMR spectroscopy
- Cryo-electron microscopy

3. Active Site Identification-The binding pocket or active site responsible for ligand interaction is identified using computational tools.

4. Molecular Docking



Potential drug molecules are virtually fitted into the active site to predict binding affinity and orientation.

5. Lead Optimization

Chemical modifications are performed to improve:

- Biological activity
- Selectivity
- Solubility
- Pharmacokinetic properties
- Toxicity profile

6. Experimental Validation

The optimized compounds are synthesized and evaluated using biological assays.

Advantages of SBDD

- Reduces time and cost of drug discovery
- Increases probability of identifying potent lead compounds
- Provides detailed understanding of ligand–protein interactions
- Enables rational drug optimization
- Facilitates development of selective drugs with fewer side effects

Applications of SBDD

Structure-based drug design is widely used in:

- Cancer therapy
- Antiviral drug discovery
- Antibiotic development
- Cardiovascular disease treatment
- Neurological disorder research

Several marketed drugs, including HIV protease inhibitors and kinase inhibitors, were developed using SBDD approaches.

Limitations of SBDD

- Requires accurate protein structure information
- Protein flexibility may complicate docking studies
- Computational predictions may not always correlate with biological activity

- Experimental validation is still necessary

Conclusion

Structure-Based Drug Design has become an essential tool in pharmaceutical research and computational chemistry. The integration of artificial intelligence, molecular modeling, and high-performance computing is further enhancing the efficiency and accuracy of SBDD in modern drug discovery.

3.2 Ligand-Based Drug Design (LBDD)

It is a computational drug discovery approach that utilizes information from known biologically active compounds (ligands) to identify and design new therapeutic molecules. Unlike Structure-Based Drug Design (SBDD), LBDD does not require the three-dimensional structure of the target protein. Instead, it relies on the chemical and biological properties of previously identified active molecule**s**.

LBDD is particularly useful when the structure of the biological target is unknown or difficult to determine experimentally.

Principle of LBDD

The principle of ligand-based drug design is based on the assumption that compounds with similar chemical structures often exhibit similar biological activities. By analyzing the structural and physicochemical properties of known active ligands, researchers can predict and design new compounds with enhanced activity and selectivity.

The method identifies important molecular features responsible for biological activity, known as pharmacophoric features, such as:

- Hydrogen bond donors and acceptors
- Aromatic rings
- Hydrophobic groups
- Charged functional group

Steps Involved in LBDD

1. Collection of Known Active Ligands

A dataset of compounds with confirmed biological activity against a specific target is collected.

2. Molecular Descriptor Calculation





Physicochemical and structural descriptors such as molecular weight, logP, hydrogen bonding capacity, and topological parameters are calculated.

3. Pharmacophore Modeling

A pharmacophore model is generated to identify essential structural features responsible for biological activity.

4. QSAR Analysis

Quantitative Structure–Activity Relationship (QSAR) models establish mathematical relationships between molecular descriptors and biological activity.

5. Virtual Screening

Large chemical databases are screened computationally to identify molecules with similar pharmacophoric and physicochemical properties.

6. Lead Optimization

Promising lead compounds are chemically modified to improve:

- Potency
- Selectivity

- Solubility
- Pharmacokinetic properties
- Toxicological profile

Major Techniques Used in LBDD

Pharmacophore Modeling

Identifies common structural features essential for activity among active compounds.

QSAR Modeling

Predicts biological activity using statistical and machine learning models.

Similarity Searching

Searches chemical databases for compounds structurally similar to known active ligands.

Machine Learning Approaches

Artificial intelligence and deep learning models are increasingly used to predict drug activity and optimize molecular structures.

Advantages of LBDD

- Does not require protein crystal structure
- Faster and cost-effective approach
- Useful for targets with unknown structures
- Facilitates virtual screening of large databases
- Enhances lead identification and optimization

Applications of LBDD

Ligand-based approaches are extensively used in:

- Anticancer drug discovery
- Antiviral and antibacterial research
- CNS drug development
- Anti-inflammatory drug design
- Cardiovascular therapeutics

Many successful drugs have been developed using QSAR and pharmacophore-based approaches.

Limitations of LBDD

- Depends heavily on availability of known active ligands

- Prediction accuracy may decrease with limited datasets.
- Structural diversity of compounds can affect model reliability.
- Cannot directly predict protein–ligand interactions

Conclusion

Ligand-Based Drug Design is an important computational strategy in modern pharmaceutical research. The integration of cheminformatics, artificial intelligence, and machine learning has significantly improved the predictive power of LBDD approaches. It continues to play a major role in accelerating drug discovery and lead optimization processes.

3.3 Fragment-Based Drug Design

It is a modern drug discovery approach in which small chemical fragments with low molecular weight are identified and optimized into potent lead compounds. Instead of screening large and complex molecules, FBDD focuses on simple molecular fragments that bind weakly to the biological target but exhibit high binding efficiency**.**

This strategy has become highly important in medicinal chemistry because it allows efficient exploration of chemical space and facilitates the development of selective and potent therapeutic agents.

Principle of Fragment-Based Drug Design

The principle of FBDD is based on identifying small molecular fragments capable of binding to different regions of a target protein. Although these fragments show weak binding affinity individually, they possess high ligand efficiency and can be optimized into larger molecules with improved potency.

Fragments generally have:

- Low molecular weight (usually <300 Da)
- Simple chemical structures
- Fewer functional groups
- High binding efficiency

The identified fragments are subsequently modified, linked, or expanded to generate lead compounds with enhanced biological activity.

Steps Involved in FBDD

1. Target Selection and Validation

A therapeutically relevant biological target such as an enzyme or receptor is identified and validated.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203

2. Fragment Library Preparation





A library containing hundreds to thousands of small molecular fragments is prepared for screening.

3. Fragment Screening

Fragments are screened against the target protein using sensitive biophysical techniques such as:

- Nuclear Magnetic Resonance (NMR) spectroscopy
- X-ray crystallography
- Surface Plasmon Resonance (SPR)
- Thermal shift assays

These methods help identify fragments capable of binding to the target.

4. Hit Identification

Fragments showing measurable binding interactions are selected as fragment hits.

5. Fragment Optimization

The identified fragments are optimized using strategies such as:

- Fragment growing
- Fragment linking
- Fragment merging

These approaches improve potency, selectivity, and pharmacokinetic properties.

6. Lead Development

Optimized compounds are further evaluated through biological and preclinical studies.

Fragment Optimization Strategies

Fragment Growing

Additional functional groups are added to the fragment to improve interactions with the target protein.

Fragment Linking

Two nearby fragments binding at adjacent sites are chemically linked to produce a more potent molecule.

Fragment Merging

Structural elements from different fragments are combined into a single optimized compound.

Advantages of FBDD

- Efficient exploration of chemical space
- Requires smaller compound libraries compared to high-throughput screening
- High ligand efficiency

- Facilitates identification of novel scaffolds
- Improves selectivity and optimization potential
- Cost-effective drug discovery approach

Applications of FBDD

Fragment-based approaches are widely applied in:

- Cancer drug discovery
- Antiviral and antibacterial drug development
- Neurological disorder therapeutics
- Enzyme inhibitor development
- Kinase-targeted therapies

Several approved drugs, such as BRAF inhibitors and kinase inhibitors, have been developed using fragment-based strategies.

Limitations of FBDD

- Fragment binding affinity is usually weak
- Requires highly sensitive screening techniques
- Optimization process can be time-consuming
- Structural information of the target protein is often necessary

Role of Artificial Intelligence in FBDD



Artificial intelligence and machine learning are increasingly integrated into FBDD for:

- Predicting fragment binding affinity
- Designing optimized lead compounds
- Improving fragment linking strategies
- Predicting toxicity and pharmacokinetic properties

AI-assisted fragment optimization has significantly accelerated the lead discovery process.

Conclusion

Fragment-Based Drug Design is an advanced and highly effective approach in modern pharmaceutical research. By utilizing small molecular fragments and combining them with computational techniques, researchers can develop potent and selective therapeutic agents more efficiently. The integration of artificial intelligence and structural biology is expected to further enhance the success of FBDD in future drug discovery programs.

.

3.4 AI-Driven Generative Drug Design

it is an advanced computational approach in which artificial intelligence (AI) models are used to generate novel drug molecules with desired biological and physicochemical properties. Unlike traditional drug discovery methods that depend on screening existing chemical libraries, generative AI models can design entirely new molecular structures computationally.

This technology combines machine learning, deep learning, cheminformatics, and computational chemistry to accelerate the identification and optimization of lead compounds. AI-driven drug design has significantly reduced the time and cost associated with pharmaceutical research and development.

Principle of AI-Driven Generative Drug Design

The principle of generative drug design is based on training artificial intelligence models using large datasets of chemical compounds and biological activities. These models learn molecular patterns, structural relationships, and pharmacological properties, enabling them to generate novel compounds predicted to possess therapeutic activity.

The generated molecules are optimized based on:

- Binding affinity
- Drug-likeness
- Selectivity
- Toxicity profile
- Pharmacokinetic properties
- Synthetic accessibility

AI systems can rapidly explore vast chemical spaces that are difficult to investigate using conventional methods.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203

Workflow of AI-Driven Drug Design

1. Data Collection and Preparation

Large datasets containing chemical structures, biological activities, and pharmacological properties are collected from databases such as:

- ChEMBL
- PubChem
- DrugBank
- ZINC database

2. Feature Extraction and Molecular Representation



Molecules are represented using:

- SMILES notation
- Molecular fingerprints
- Graph-based representations
- Molecular descriptors

These representations are used as inputs for machine learning models.

3. Model Training

AI models are trained using known chemical and biological data to learn structure–activity relationships.

4. Molecular Generation

The trained model generates new molecular structures predicted to possess desired pharmacological properties.

5. Virtual Screening and Optimization

Generated compounds undergo:

- Molecular docking
- QSAR analysis
- Toxicity prediction
- ADMET profiling
- Lead optimization

6. Experimental Validation

Promising molecules are synthesized and evaluated using laboratory experiments.

Types of AI Models Used

Recurrent Neural Networks (RNNs)

RNNs generate molecular sequences using SMILES representations and are widely used in molecular generation.

Generative Adversarial Networks (GANs)



GANs consist of generator and discriminator networks that collaboratively generate realistic and optimized molecular structures.

Variational Autoencoders (VAEs)

VAEs encode molecular information into latent space and generate chemically valid molecules.

Graph Neural Networks (GNNs)

GNNs directly analyze molecular graphs and improve prediction of molecular interactions and biological activity.

Reinforcement Learning

Reinforcement learning algorithms optimize molecules by rewarding desirable properties such as potency and low toxicity.

Applications of AI-Driven Generative Drug Design

AI-driven approaches are extensively used in:

- Anticancer drug discovery
- Antiviral and antibacterial drug development
- Neurological disorder therapeutics
- Personalized medicine
- Rare disease treatment
- Protein-targeted drug design

AI-generated molecules have already entered preclinical and clinical development stages in several pharmaceutical companies.

Advantages of AI-Driven Drug Design

- Accelerates drug discovery process
- Reduces research and development costs
- Generates novel chemical entities
- Improves prediction accuracy
- Enables rapid optimization of lead compounds
- Facilitates personalized medicine approaches

Challenges and Limitations

Despite significant advancements, several limitations remain:

- Dependence on high-quality datasets
- Bias in training data
- Difficulty in predicting biological complexity
- Synthetic feasibility concerns
- Regulatory and ethical considerations
- Requirement for experimental validation

AI-generated compounds may not always demonstrate expected biological activity in real-world laboratory conditions.

Future Perspectives

The future of AI-driven drug design is highly promising. Integration of:

- Quantum computing
- Multi-omics data
- Cloud computing
- Autonomous laboratories
- Digital twins in healthcare

may further revolutionize pharmaceutical research.

Collaboration between artificial intelligence experts, medicinal chemists, and regulatory agencies will play a crucial role in the successful adoption of AI-driven drug discovery technologies.

Conclusion

AI-Driven Generative Drug Design represents a transformative advancement in modern pharmaceutical sciences. By combining artificial intelligence with computational chemistry and biological data analysis, researchers can design innovative therapeutic molecules more efficiently than traditional methods. Continuous advancements in deep learning and computational power are expected to further accelerate the development of safe, effective, and personalized medicines in the future.

4. Computational Techniques in De Novo Drug Design

4.1 Molecular Docking

Molecular docking is a computational technique used to predict the interaction between a ligand (drug molecule) and a target protein. It helps determine the preferred orientation of the ligand within the active site of the protein and estimates the binding affinity of the complex. Docking studies are widely used in drug discovery to identify potential lead compounds, understand molecular interactions, and optimize drug candidates before experimental studies.

4.2 Molecular Dynamics Simulation



International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203



Molecular dynamics (MD) simulation is a computational method used to study the physical movement of atoms and molecules over time. It provides detailed information regarding protein flexibility, ligand stability, conformational changes, and molecular interactions under physiological conditions. MD simulations are useful for evaluating the stability of protein–ligand complexes and improving the accuracy of drug design studies.

4.3 Quantitative Structure–Activity Relationship (QSAR)



International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203

QSAR is a computational approach that establishes mathematical relationships between molecular properties and biological activity. It uses molecular descriptors such as hydrophobicity, molecular weight, electronic properties, and steric factors to predict the activity of chemical compounds. QSAR models assist researchers in identifying promising drug candidates and reducing the need for extensive laboratory testing.

4.4 Pharmacophore Modeling





Pharmacophore modeling is a ligand-based computational technique used to identify the essential structural features responsible for biological activity. These features may include hydrogen bond donors, hydrogen bond acceptors, aromatic rings, hydrophobic regions, and charged groups. Pharmacophore models are widely used in virtual screening to identify compounds with similar biological properties.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 ijppr.humanjournals.com ISSN: 2349-7203

4.5 Virtual Screening





Virtual screening is a computational technique used to rapidly evaluate large chemical libraries to identify potential lead compounds with desired biological activity. It involves molecular docking, pharmacophore modeling, and QSAR approaches to prioritize compounds for experimental testing. Virtual screening significantly reduces the time, cost, and effort associated with traditional high-throughput screening methods in drug discovery.

5. Role of Artificial Intelligence and Machine Learning

Artificial intelligence has revolutionized drug discovery by automating molecular generation and optimization. Machine learning models analyze large chemical datasets to identify patterns associated with biological activity.

Deep learning approaches such as convolutional neural networks and graph neural networks can predict drug–target interactions with high accuracy. Reinforcement learning methods optimize molecular properties including solubility, potency, and selectivity.

AI-based platforms have significantly reduced the time required for lead identification. Pharmaceutical companies are increasingly integrating AI tools for target prediction, biomarker discovery, and toxicity assessment.

6. Applications of De Novo Drug Design

De novo drug design has diverse pharmaceutical applications.

6.1 Cancer Therapy

Computational drug design has enabled development of kinase inhibitors, monoclonal antibodies, and targeted anticancer agents.

6.2 Antimicrobial Drug Discovery

Novel antibiotics and antiviral compounds have been identified through AI-driven molecular generation.

6.3 Neurological Disorders

Drug candidates targeting Alzheimer's disease, Parkinson's disease, and epilepsy have been designed using structure-based approaches.

6.4 Cardiovascular Diseases

Computational methods assist in identifying selective inhibitors for hypertension, thrombosis, and hyperlipidemia.

6.5 Rare and Personalized Diseases

Precision medicine approaches utilize genomic data for individualized drug development.

7. Advantages of De Novo Drug Design

The major advantages include:

• Reduction in research and development costs

• Faster lead identification and optimization

• Improved prediction of biological activity

• Enhanced selectivity and reduced toxicity

• Ability to explore vast chemical space

• Better integration with personalized medicine approaches

8. Challenges and Limitations

Despite significant advancements, several limitations remain.

• Limited accuracy of predictive models

• Difficulty in predicting long-term toxicity

• Synthetic accessibility issues

• Data quality and bias in AI models

• Regulatory uncertainty associated with AI-generated compounds

• Computational resource requirements

Experimental validation remains essential to confirm computational predictions.

9. Future Perspectives

Future developments in de novo drug design are expected to involve autonomous AI systems capable of performing end-to-end drug discovery. Integration of quantum computing, cloud-based simulations, and multi-omics data analysis may further improve molecular prediction accuracy.

Personalized medicine and precision therapeutics are likely to benefit substantially from AI-assisted molecular design. Collaborative efforts between computational scientists, medicinal chemists, and regulatory agencies will be essential for successful implementation.

10. Conclusion

De novo drug design represents a powerful and rapidly evolving approach in modern pharmaceutical research. Advances in artificial intelligence, machine learning, and computational chemistry have significantly enhanced the ability to design novel therapeutic agents with improved efficacy and safety profiles. Although several challenges remain, continuous technological progress and interdisciplinary collaboration are expected to transform drug discovery processes in the coming decades.

REFERENCES

1. Schneider G. De novo drug design. Nature Reviews Drug Discovery. 2018;17(2):97-113.
2. Lounkine E, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012;486:361-367.
3. Lionta E, et al. Structure-based virtual screening for drug discovery. Current Topics in Medicinal Chemistry. 2014;14(16):1923-1938.
4. Zhavoronkov A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology. 2019;37:1038-1040.
5. Sliwoski G, et al. Computational methods in drug discovery. Pharmacological Reviews. 2014;66:334-395.
6. Kitchen DB, et al. Docking and scoring in virtual screening. Nature Reviews Drug Discovery. 2004;3:935-949.
7. Jorgensen WL. The many roles of computation in drug discovery. Science. 2004;303:1813-1818.
8. Mullard A. AI in drug discovery. Nature Reviews Drug Discovery. 2019;18:463-464.
9. Brown N. Chemoinformatics and de novo molecular design. Wiley Interdisciplinary Reviews. 2019;9:e1396.
10. LeCun Y, et al. Deep learning. Nature. 2015;521:436-444.
11. Cherkasov A, et al. QSAR modeling: where have you been? Journal of Medicinal Chemistry. 2014;57:4977-5010.
12. Gilmer J, et al. Neural message passing for quantum chemistry. Proceedings of ICML. 2017.
13. Segler MHS, et al. Planning chemical syntheses with deep neural networks. Nature. 2018;555:604-610.
14. Walters WP, Murcko MA. Prediction of drug-likeness. Advanced Drug Delivery Reviews. 2002;54:255-271.
15. Macalino SJY, et al. Role of computer-aided drug design in modern drug discovery. Archives of Pharmacal Research. 2015;38:1686-1701.
16. Stahl M, Rarey M. Detailed analysis of scoring functions for docking. Journal of Medicinal Chemistry. 2001;44:1035-1042.
17. Vamathevan J, et al. Applications of machine learning in drug discovery. Nature Reviews Drug Discovery. 2019;18:463-477.
18. Yang X, et al. Concepts of artificial intelligence for computer-assisted drug discovery. Chemical Reviews. 2019;119:10520-10594.
19. Polishchuk PG. Artificial intelligence in drug discovery. Future Medicinal Chemistry. 2019;11:1843-1845.
20. Hughes JP, et al. Principles of early drug discovery. British Journal of Pharmacology. 2011;162:1239-1249.
21. Bleicher KH, et al. Hit and lead generation: beyond high-throughput screening. Nature Reviews Drug Discovery. 2003;2:369-378.
22. Shoichet BK. Virtual screening of chemical libraries. Nature. 2004;432:862-865.
23. Bajorath J. Integration of virtual and high-throughput screening. Nature Reviews Drug Discovery. 2002;1:882-894.
24. Ekins S. The next era: deep learning in pharmaceutical research. Pharmaceutical Research. 2016;33:259-267.
25. Pereira JC, et al. Machine learning methods in drug discovery. Molecules. 2016;21:973.
26. Coley CW, et al. Machine learning in computer-aided synthesis planning. Accounts of Chemical Research. 2018;51:1281-1289.
27. Gawehn E, et al. Deep learning in drug discovery. Molecular Informatics. 2016;35:3-14.
28. Mendez D, et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Research. 2019;47:D930-D940.
29. Gaulton A, et al. The ChEMBL database in 2017. Nucleic Acids Research. 2017;45:D945-D954.
30. Silver D, et al. Mastering the game of Go with deep neural networks. Nature. 2016;529:484-489.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 **ijppr.humanjournals.com** ISSN: 2349-7203

How to cite this article:
Rutuja Gaikwad Ijppr.Human, 2026; Vol. 32 (5): 446-467.

Conflict of Interest Statement: All authors have nothing else to disclose.